Capricor Therapeutics, Inc.
General ticker "CAPR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $963.2M (TTM average)
Capricor Therapeutics, Inc. follows the US Stock Market performance with the rate: 7.0%.
Estimated limits based on current volatility of 7.3%: low 9.79$, high 11.33$
Factors to consider:
- Total employees count: 231 (+44.4%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Insufficient capital, Regulatory and compliance, Clinical trial failure, Manufacturing risks, Market competition
- Current price 23.3% below estimated low
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [12.89$, 32.06$]
- 2026-12-31 to 2027-12-31 estimated range: [8.72$, 23.02$]
Financial Metrics affecting the CAPR estimates:
- Negative: with PPE of -13.0 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -5.11 <= 0.28
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Negative: negative Industry operating income (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Shareholder equity ratio, % of 85.91 > 63.63
Short-term CAPR quotes
Long-term CAPR plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $25.18MM | $22.27MM | $0.00MM |
| Operating Expenses | $49.26MM | $64.84MM | $108.14MM |
| Operating Income | $-24.08MM | $-42.56MM | $-108.14MM |
| Non-Operating Income | $1.79MM | $2.10MM | $3.10MM |
| Interest Expense | $0.00MM | $0.00MM | $3.05MM |
| R&D Expense | $36.45MM | $49.97MM | $84.45MM |
| Income(Loss) | $-22.29MM | $-40.47MM | $-105.04MM |
| Taxes | $0.00MM | $0.00MM | $0.00MM |
| Net Income(Loss)* | $-22.29MM | $-40.47MM | $-105.04MM |
| Stockholders Equity | $22.60MM | $145.46MM | $305.79MM |
| Assets | $58.73MM | $170.48MM | $355.95MM |
| Operating Cash Flow | $-25.60MM | $-40.00MM | $-69.81MM |
| Capital expenditure | $2.05MM | $1.54MM | $2.90MM |
| Investing Cash Flow | $5.11MM | $-116.18MM | $97.48MM |
| Financing Cash Flow | $25.58MM | $152.77MM | $248.89MM |
| Earnings Per Share** | $-0.83 | $-1.15 | $-2.26 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.